Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04120051
Other study ID # H-19041432
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 28, 2019
Est. completion date March 31, 2020

Study information

Verified date November 2019
Source University of Copenhagen
Contact Mads V Lind, PhD
Phone 35 33 10 91
Email madslind@nexs.ku.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Modulation of the gut microbiota via administration of pro- and prebiotics have been proposed to contribute to weight loss and reduce plasma glucose and serum lipid levels, improving the inflammatory state and decreasing the incidence of type 2 diabetes and cardiovascular disease. This study will test a fermented canola-seaweed (FCS) product, high in glucosinolates and putatively prebiotic oligosaccharides, in human subjects with obesity.


Description:

The overall objective of this study is to investigate a fermented canola-seaweed (FCS) product in obese human subjects with increased risk of metabolic syndrome (MS). We will study the effects of the FCS on glucose handling and related cardiometabolic traits such as dyslipidemia and low-grade systemic inflammation. Finally, we will examine the gut microbiota and the metabolic phenotype of the subjects to explore molecular mechanisms related to the potential improvements.

It is hypothesized that the FCS product will improve postprandial glucose handling, blood lipids and low-grade inflammation in obese subjects with increased risk of MS. Furthermore, it is hypothesized that this effect is modified through gut microbiota compositional and functionality changes

Methods:

This study will be conducted as a randomized, controlled, investigator and participant blinded intervention trial. The participants will be randomized to the FCS supplement or control and are expected to consume one sachet of either every day for 6 weeks.

Randomization, blinding and allocation concealment:

After having given oral and written consent, randomization will be performed separately for each participant in blocks of variable size to ensure equal randomization throughout the enrolment phase of the study. The randomization sequence will be done by an investigator without contact to the participants. The personnel conducting the study will allocate participants to the sequence of intervention using a list of participant identification numbers matched with allocated sequences. The participants will be blinded to the intervention and blinding of the allocation sequence will be present for investigators during sample analysis and initial data analysis.

Examinations:

Participants will arrive for clinical examination after an overnight fast of at least 8 hours. Lifestyle questionnaires and questionnaires about medication use will be performed for baseline characterization of the participants. Blood pressure and anthropometric measurements are performed including measurements of body weight, height, waist and hip circumference, and bio-impedance measurements for assessing body fat mass. A fasting blood sample is obtained and an oral glucose tolerance test (OGTT) is performed with collection of blood samples after 0, 30 and 120 min. Samples will be analyzed with standard clinical procedures for glycaemic variability markers, including glucose, insulin, c-peptide, and HbA1c, as well as plasma lipids. Furthermore, fecal samples will be collected at both examination visits and kept stored for future microbiota analyses, using untargeted shotgun sequencing.

Samples in biobank will be stored for further analyses, which could include gastrointestinal hormones, gut microbiota metabolites, blood, and fecal metabolome and low-grade inflammation markers. In addition, a subgroup of participants (10 in each group) will be equipped with a 24-h continuous glucose monitoring device for 14 days at the start of the intervention period. Both examination days consists of similar examinations and data collections and are estimated to last approximately 2½ hours.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date March 31, 2020
Est. primary completion date March 31, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 65 Years
Eligibility Inclusion Criteria:

- Participants who have provided written informed consent

- Age between 30 and 65 years

- Body mass index =31 kg/m^2

Exclusion Criteria:

- Body mass index <31 kg/m^2

- Diagnosis of diabetes (HbA1c = 6,5% (48 mmol/mol)) or pharmacological treatment of diabetes

- Use of peroral glucocorticoids

- Lack of compliance with the procedures (ingestion of sachets) in the study protocol, judged by Investigator

- Ingestion of pre- or probiotic supplements during the study and 14 days prior to study start

- Use of systemic antibiotics 1 month prior to study start

- Use of cholesterol lowering drugs

- Have had an obesity or abdominal surgery

- Chronic inflammation disorders (excluding obesity)

- Diagnosed psychiatric disorder including depression requiring treatment

- Gastro intestinal and liver disorders

- Gluten intolerance

- Maltodextrin intolerance

- Intensive physical training/ elite athlete (>10 hours of strenuous physical activity per week)

- Pregnant or lactating

- High intake of alcohol (>14 drinks/week for women and >21 drinks/week for men)

- Simultaneous blood donation for other purpose than this study

- Simultaneous participation in other clinical intervention studies

- Inability, physically or mentally, to comply with the procedures required by the study protocol as evaluated by the principal investigator or clinical responsible.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Fermented canola-seaweed
A daily sachet with 5 gram FCS-granulate for 6 weeks
Other:
Placebo
A daily sachet with 5 gram rye cereal for 6 weeks

Locations

Country Name City State
Denmark University of Copenhagen Frederiksberg Danmark

Sponsors (2)

Lead Sponsor Collaborator
University of Copenhagen FermBiotics ApS

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary changes in 2-h post-OGTT glucose in blood between baseline and endpoint 2 hour post oral glucose tolerance test glucose measurement in blood (mmol/L) Week 0 and Week 6
Secondary Changes in Hba1c between baseline and endpoint fasting measurement of blood glycated hemoglobin (%) Week 0 and Week 6
Secondary Changes in fasting blood glucose between baseline and endpoint Fasting measurement of blood glucose (mmol/L) Week 0 and Week 6
Secondary Changes in 30 min post OGTT between baseline and endpoint Measurement of blood glucose 30 min after OGTT (mmol/L) Week 0 and Week 6
Secondary Insulin sensitivity and secretion Measured as part of the OGTT. Plasma glucose (mmol/l). Plasma insulin - fasting (pmol/l) Week 0 and Week 6
Secondary Changes in blood lipids between baseline and endpoint Measurements of total and HDL cholesterol (mmol/L) and triglycerides (mmol/L) Week 0 and Week 6
Secondary Changes in C-Reactive Protein between baseline and endpoint Blood measurements of C-Reactive Protein (mg/L) Week 0 and Week 6
Secondary Changes in Interleukin-6 between baseline and endpoint Blood measurements of Interleukin-6 (pg/mL) Week 0 and Week 6
Secondary Changes in small metabolites between baseline and endpoint Measured using blood metabolomic measurements of amino acids, lipids, and other small metabolites (umol/L) Week 0 and Week 6
Secondary Changes in weight between baseline and endpoint Measured using a Tanita body composition analyser. Body weight in kilograms Week 0 and Week 6
Secondary Changes in waist circumference between baseline and endpoint Measured using measurement tape Week 0 and Week 6
Secondary Changes in body composition between baseline and endpoint Measured using a Tanita body composition analyser. Fat free mass and Body fat mass in kilograms used to calculate body fat percentage. Week 0 and Week 6
Secondary Changes in blood pressure (BP) between baseline and endpoint Systolic BP (mmHG) Diastolic BP (mmHG) Week 0 and Week 6
Secondary Continuous glucose monitoring Continuous glucose monitor from Abbott is worn for 14 days in each period providing glucose measurements continuously (mmol/L) Week 0
Secondary Changes in Liver function markers Alanine transaminase (ALAT) (U/L), Aspartate transaminase (ASAT) (U/L) Week 0 and week 6
Secondary Changes in circulating endotoxin/lipopolysaccharide (LPS) concentrations LPS (pg/ml) Week 0 and Week 6
Secondary Changes in gut microbiota composition Measured on fecal samples Week 0 and Week 6
See also
  Status Clinical Trial Phase
Recruiting NCT04635202 - Effect of Elliptical Training on Metabolic Homeostasis in Metabolic Syndrome N/A
Completed NCT04053686 - An Intervention to Reduce Prolonged Sitting in Police Staff N/A
Completed NCT05343858 - Pilot Study to Evaluate the Effect of Two Microalgae Consumption on Metabolic Syndrome N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Recruiting NCT05040958 - Carotid Atherosclerotic Plaque Load and Neck Circumference
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Completed NCT03289897 - Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan N/A
Recruiting NCT05956886 - Sleep Chatbot Intervention for Emerging Black/African American Adults N/A
Completed NCT06057896 - Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
Active, not recruiting NCT03613740 - Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion Phase 2
Completed NCT04498455 - Study of a Prebiotic Supplement to Mitigate Excessive Weight Gain Among Physicians in Residency Phase 4
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT03697382 - Effect of Daily Steps on Fat Metabolism N/A
Completed NCT03241121 - Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome N/A
Completed NCT04509206 - Virtual Teaching Kitchen N/A
Completed NCT05124847 - TREating Pediatric Obesity N/A